Meningiomas are often organized with the WHO clas sification of tumors, with 80% being considered Grade I (benign); 10%-15%, Grade II (atypical); and 2%-5%, Grade III (anaplastic/malignant).
9 Grade III meningiomas are typically associated with brain invasion and recur rence, and the overall 10year survival rate for patients with these lesions is only 14.2%. 22 Thus, it is of critical clinical significance to accurately determine the characteristics of these tumors in a timely fashion. The WHO pathological grading system cannot always accurately predict the clini cal aggressiveness of these tumors, and grading is subject to sampling error and interuser variability. 38 Additional possible explanations for the difficulty in predicting the behavior of meningiomas have included the observations that there are numerous histological similarities between tumors in each grade and that these tumors exist along a spectrum in which lowgrade meningiomas can progress to a higher grade. 2 There is no clear explanation, however, as to why the majority of recurrent meningiomas derive from benign histology even after apparently radical removal. 55 Other attempts to classify meningiomas have used genomic techniques to study their genesis and progres sion, 73 as well as to search for genetic mutations and variable gene expression mediated via epigenetic modi fications. 35 The use of epigenomics as a clinical tool has become better understood in recent years 47 and research has started to elucidate the importance of epigenetics in meningioma progression. Data suggest that there is an absence of any significant genetic alterations in nearly 40% of meningiomas.
31, 52 One study found that 77% of meningiomas had at least 1 methylated gene, and 25% of samples in another study had 3 or more methylated genes. 5 Epigenetic alterations in the genome are also par A review of epigenetic and gene expression alterations associated with intracranial meningiomas ticularly useful to examine because they are thought to occur in the early stages of tumorigenesis 35 and can func tion through multiple mechanisms to cause runaway cell growth (Fig. 1) .
In this review, we present a systematic analysis of the genes that are known to undergo epigenetic modifications as related to the development, progression, and recurrence of intracranial meningiomas. This article summarizes the literature pertaining to the epigenetic modification of meningiomas and provides a brief discussion for future avenues of molecular classification, prognosis, and epi genetic therapies (epidrugs), that could provide significant clinical value to patients with meningiomas in the future.
Methods
A systematic review of the PubMed database was performed to identify all studies published up to Au gust 2012, using all combinations of the search terms "meningioma," "epigenetics," "methylation," "histone," "sequencing," and "acetylation." Only Englishlanguage publications were included in our query. Two investiga tors independently screened all identified abstracts for potential inclusion. To be considered eligible for inclu sion, a study looked at the epigenetic changes to menin giomas defined as alterations in levels of gene expression that are not accompanied by changes in the primary DNA sequence.
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Results
A primary and secondary review of all identified ab stracts resulted in 138 studies that met initial inclusion criteria. Of these studies, 112 were discarded due to 1) identified changes in the underlying DNA sequence or 2) publication in a language other than English. The result ing 26 studies from the systematic search were then clas sified according to gene subtype affected by epigenetic modification.
Tumor Suppressor Genes
The best understood of the tumor suppressor genes as pertaining to epigenetic regulation of meningiomas is the TIMP3 (TIMP metallopeptidase inhibitor 3 or tissue inhibitor of metalloproteinase 3), which encodes for a protein that inhibits matrix metalloproteinases (MMPs) ( Table 1) . A second function appears to be a unique tu mor suppressor-like property that is not related to MMP inhibition. 3 Overexpression of TIMP3 in vitro has been shown to suppress tumor growth and induce apoptosis. Hypermethylation of the 22q12 gene TIMP3 and subse quent transcriptional downregulation (gene silencing) has been identified as a marker for an aggressive, high-grade meningioma phenotype. 4, 49 Although there is some minor disagreement in the literature, Grade I tumors have been found to have significantly less aberrant methylation at TIMP3 than Grade II or III meningiomas.
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The urokinase plasminogen activator (uPA) system functions via extracellular matrix proteolysis to facilitate cellular adhesion and migration. 51 Active uPA activates plasminogen to plasmin, which degrades the extracellular matrix and activates various MMPs, 1 intersecting with the pathway of TIMP3. Increased expression of uPA pro teins is associated with higher WHO grade, malignant invasion, and recurrence. 40, 85 TP53. Tumor suppressor p53 (cellular tumor antigen p53, p53) is a ubiquitous component in growth regulation that interacts with multiple other pathways to control the cell cycle. Loss of chromosome 9 is of particular impor Fig. 1 . Two possible mechanisms for oncogenesis via epigenetic modifications. Upper: A proto-oncogene is demethylated, allowing for transcription factors to bind and express the oncogenic product, allowing runaway cellular growth. Lower: A normally unmethylated tumor suppressor gene becomes methylated through epigenetic modifications, inhibiting transcription and thus leading to proliferation of meningioma through loss of function.
tance because of 3 notable tumor suppressor genes lo cated on its short arm. CDK2NA (p14 [ARF] ) is a gene on the 9p21 locus that interacts with TP53 and regulates the transition from the G 1 /S-phase checkpoint. Previous mu tational studies of CDK2NA (p14 [ARF] ) have shown that allelic losses, including homozygous deletions at 9p21, are important components of the progression of atypi cal and anaplastic meningiomas. 8 The p14ARF (cyclindependent kinase inhibitor 2A, isoform 4) protein binds to the MDM2 oncogene (MDM2) and promotes the rapid degradation of the MDM2 regulator protein, preventing the degradation of p53. 99 Methylation and inhibition of this pathway consequently increases p53 breakdown and prevents the normal cell cycle checkpoint function. Inac tivation of this p14ARF and p53 pathway through hyper methylation has been shown to occur frequently in human brain tumors. 97 The tumor suppressor protein p73, which shares sig nificant sequence homology with p53, 39 also plays an im portant role in malignant meningiomas.
14,22 Previous re search has indicated that p73 has opposing functions of both cell growth and cell cycle arrest. 58 Epigenetic studies show that p73 plays a similar dual role in meningioma progression. Hypermethylation may cause development of some lowgrade forms, whereas enhanced p73 expres sion characterizes malignant meningiomas.
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HIST1H1c. Histone cluster 1, H1c is a gene on chro mosome 6 that has been found to be overexpressed in 27% and 89% of original and recurrent meningiomas, respectively, in a study by PérezMagán et al. 69 It is hy pothesized that the physical interaction of the H1.2 pro tein can participate in the epigenetic regulation of gene expression by maintaining specific DNA methylation pat terns. 24 More specifically, the authors hypothesize that it may suppress p53dependent p300mediated chromatin transcription by blocking chromatin acetylation.
The importance of p53 in preventing meningioma de velopment and grade extends to another gene, MEG3 (maternally expressed 3) , an imprinted gene with maternal ex pression that encodes a noncoding RNA. Previous research showed that MEG3 RNA functions by activating p53 target genes and stimulates p53mediated transcriptional activa tion. 100 Zhang et al. 98 hypothesized that since MEG3 is lo cated at 14q32, a region that has been previously associ ated with meningioma progression, it would be an ideal candidate for epigenetic meningioma progression. Their research showed that MEG3 RNA is highly expressed in normal arachnoidal cells but not expressed in the major ity of meningiomas, whereas highgrade meningiomas fre quently show a higher degree of MEG3 methylation (p = 0.038) as well. Furthermore, when MEG3 cDNA was test ed in vitro on meningioma cell lines, the gene was found to suppress colony formation by 80%, similar to the rate of other known growth suppressors. The study illustrates the importance of epigenetic regulation of p53 as a key inhibi tor of meningiomas.
Atypical anaplastic meningiomas show higher ex pression of the GADD45A gene 94 when compared with benign meningiomas, similar to increases previously found in pancreatic carcinomas. 96 Three additional genes were identified by Wrobel et al. through mRNA expres sion and immunohistochemistry as having a stronger ex pression profile in atypical and anaplastic meningiomas than benign meningiomas: PCNA, STK15 (AURKA), and CENPF. 94 PCNA interacts with GADD45A (GADD45) and functions as a cofactor for DNA polymerase, caus ing cell proliferation. 56 STK15 encodes aurora kinase A, a centrosome-associated serine/threonine kinase previous ly shown to be amplified in colon cancer, 28 while CENPF encodes mitosin, a protein of centromerekinetochore complex protein that is involved in cell division of so matic cells and involved in a range of oncogenic patholo gies. 44, 86 Other tumor suppressor genes that do not involve the p53 pathway include TMEM30B and GSTP1. TEME30B is a gene in the 14q region that encodes a transmembrane factor that participates in the cell cycle.
11 It had previ ously been found to be expressed in meningiomas 41 and is downregulated in recurrences compared with nonon cogenic tissue.
17 GSTP1 is a member of the glutathioneStransferase family. Its function is to conjugate carcino gens with glutathione, which neutralizes it and allows its excretion, preventing DNA damage. 33 Hypermethylation of GSTP1 was found with an increasing frequency from 0% in benign to 32% in atypical to 54% in anaplastic variants 49 of meningiomas in one study by Liu et al., and thus GSTP1 promoter region hypermethylation is associ ated with meningioma grade. 49 
Cell Signaling
The homeobox (HOX) family of genes is a target for gene silencing via DNA comethylation 21, 83 and is fre quently identified in a wide variety of human tumorigen esis 76, 90, 95 ( Table 2 ). The concordant methylation of HOXA genes on 7p15.2, including HOXA5, HOXA6, HOXA9, and HOXA11 leads to the downregulation of tumor sup pressor targets. 45 Kishida et al. 45 used highthroughput 10, 80 Although its role in oncogenesis is still relative ly unknown, a recent study suggested that cellular stress induces PENK to physically bind with p53 and RELA (p65) to regulate stressinduced apoptosis. 57 This would seem in concordance with previous evidence that p53related path ways play an important role in meningioma epigenetically mediated oncogenesis. UPK3A codes for uroplakin3a, one of a group of transmembrane proteins that form complexes on the surface of bladder epithelium. 102 DNA methylation of the promotor region of UPK3A is the primary mecha nism underlying silencing of the gene, and such alterations have also been reported in metastasis of colorectal neo plasms.
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IGF. The IGF signaling family and the anomalous expression of IGF, IGF receptor, and IGF-binding pro teins have been demonstrated as a key signaling pathway in the tumorigenesis of meningiomas. The literature has consistently revealed that the increased expression of IGFBP3 and IGF2 transcripts, along with decreased ex pression of IBFBP2, is important in meningioma progres sion and anaplastic classification. 65, 92, 94 It was reported that IGFBP3 may potentiate IGF1 action by altering B/ AKT protein kinase sensitivity to IGF-1 receptor signal ing.
12 Furthermore, IGFBP1 is an RNA-binding protein that regulates mRNA stability and translocation. It is hy pothesized to play a role in tumorigenesis by stabilizing messenger RNAs of the c-myc oncogene and IGF2 in cer tain cancers.
45
WNK2. In meningiomas, Jun et al. found that WNK2 was aberrantly methylated in 83% and 71% of Grade II and III meningiomas, respectively, but rarely methylated in 13 other tumor types. The authors noted that aberrant methylation of the CpG island was associated with de creased gene expression in primary tumors, while expres sion of exogenous WNK2 inhibited colony formation, implicating it as a potential cell growth suppressor.
37,71
WNK2 has been shown to inhibit cell proliferation in vitro by negatively modulating the activation of MEK1/ ERK1/2 and epidermal growth factor receptor (EGFR) signaling. EGFR is thought to be an important oncogene in meningiomas, and WNK2 silencing could potentially enhance EGFR protein signaling.
60 Jun et al. showed that WNK2 could be reactivated with a methylation inhibitor in IOMM-Lee cells, and thus their findings may be trans latable to the bedside.
NDRG2. N-myc downstream regulated gene 2 (NDRG2)
is normally expressed in brain, heart, and mus cle and is one of 4 members of the NDRG family. 75 It has been implicated in cell growth as well as apoptosis, and identified by Lusis et al. as a gene that is consistently downregulated in Grade III meningioma and independent sets of diverse meningiomas. The loss of NDRG2 expres sion was significantly associated with hypermethylation of the NDRG2 promoter. 63 and is known to function in mesenchymal cell-epithelial cell interactions. The authors of the meningioma study sug gest that LMO4 modulates TGF-b signaling through its interaction with receptoractivated SMADs, supporting the finding of the downregulation of the TGF-b pathway in recurrent meningiomas. 53 Involvement of the TGF-b-SMAD pathway seems to also include the CTGF gene, 11 whose product is a growth factor secreted by vascular endothelial cells and has vari ous regulatory functions in cell growth and apoptosis. CTGF has been found to have significantly lower expres sion in recurrent meningiomas than in original meningio mas in microarray expression data (p < 0.05).
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Notch. The Notch pathway is another signaling cas cade that has been implicated in tumorigenesis through epigenetic mechanisms.
14,19,59,84 Cuevas et al. found that 45% of meningiomas of all grades have hes family bHLH transcription factor 1 (HES1, previously known as induction of hairy and enhancer of Split 1) with overexpression of the Notch receptor or the Jagged ligand, suggesting that there are multiple mechanisms activating the Notch pathway as a critically important genetic alteration in meningioma pathogenesis. 16 These findings corroborate prior work showing that HES1 is upregulated in menin gioma compared with control dural specimens.
42 Deregu lated Notch signaling represents a particularly promising therapeutic target for meningioma treatment.
MAPK.
Findings from an analysis of 10 human me ningiomas indicate that MAPK is constitutively expressed in meningioma cells, and upstream signaling factors of MAPK receptors also act as a mitogen in these menin gioma cells. Subsequent inhibition of MAPK activity also blocked upstream mitogenic stimulation of meningioma proliferation, strongly suggesting that MAPK is an im portant transducer of cell growth. Furthermore, treatment with PD098059, a MAPK inhibitor, produced progressive growth inhibition, correlating with a marked reduction in MAPK phosphorylation and reduced MAPK activ ity without changing levels of unphosphorylated MAPK (p44) and MAPK (p42) in most of the cell cultures, indi cating that MAPK inhibitors may be useful treatments for meningiomas in humans. 34 The LIF locus encodes a factor that acts upstream of the MAPK cascade. Located at the 22q chromosomal region, it is an area that is noted for its importance to meningioma pathogenesis. In one study, all of the tumor specimens were hypomethylated at the LIF locus relative to constitutional DNA from the same patients. The re searchers found a novel alternatively spliced LIF mRNA, which suggests that the LIF gene may be near a key tumor suppressor locus associated with meningioma develop ment. 70 Wnt. The Wnt signaling pathway plays a central role in meningioma tumorigenesis. Immunohistochemi cal stud ies have previously demonstrated that anaplastic me ningiomas frequently lose Ecadherin expression, 79 which are mediated by beta catenin, 46 a key Wnt signaling gene. Beta catenin is regulated by the complex of CDK5R1 and CK5.
43 When CDK5R1 is upregulated, there seems to be a reduction in beta catenin-regulated cadherin-mediated cellcell adhesion, 79 explaining previous immunohisto chemical studies that have shown this very reduction. The levels of beta catenin itself seem to increase a function of this regulatory pathway to also act as a transcription factor in the nucleus for multiple genes for the Wnt sig naling pathway, furthering its dysregulation. 81 SFRP1, in the family of frizzledrelated proteins, is able to down regulate Wnt signaling by forming an inhibitory complex with frizzled receptors. Its tumor suppressor properties have been noted in many other cancers 94 and seem to play a role in meninigioma recurrence when it is down regulated, as recurrent meningiomas showed significantly lower mRNA levels than in original meningiomas. 69 Hy permethylation of the SFPR1 promoter has been noted to have a similar effect in gliomas, adding to the increasing evidence that epigenetic mechanisms may play a key role in the Wnt signaling pathway.
Histone Acetylation
Histones and their posttranslational modification sys tem, acetylation, allow for DNA repair and the dynamic regulation of chromatin structure and function.
27 Nace tyltransferases bind various compounds to a primary aro matic amine or hydrazine structure and have been linked to various primary carcinomas of diverse epithelial tissues that include bladder cancer and colon cancer. 66 Olivera et al. 103 investigated the role of 10 different N-acetyltransferase-2 (NAT2) alleles for meningioma and astrocytoma growth. Individuals carrying rapid acetylation alleles were found to be at increased risk of developing meningioma and astrocytomas compared with healthy volunteers (OR 1.79, 95% CI 1.05-3.05; p < 0.05). It has been hypothesized that the NAT2 polymorphism may have a local effect on brain tumors by activating carcinogens. Indeed, the rapid acetylator genotype has been linked to patients with gli oma. 87 The findings in its role in tumorigenesis have not been conclusive, 72 however, and thus further studies to in vestigate its role in meningioma growth are necessary.
Angiogenesis
Epigenetic regulation of angiogenic factors may al so play an important, yet undefined role in meningioma oncogenesis. The thrombospondin 1 (THBS1) gene nor mally inhibits angiogenesis by disrupting the motility of endothelial cells and inducing their apoptosis. 29 Hyper methylation and subsequent silencing of this gene may therefore promote angiogenesis in tumor cells. 67 Bello et al. found that 54% of Grade III meningiomas and 30% of all cases of meningiomas showed hypermethylation of the THBS1 gene, 5 respectively, suggesting that its inacti vation could lead to neovascularization of atypical me ningiomas and contribute to their progression.
Other Mechanisms
Müller et al. found that chromosome 1 alkaline phosphatase (ALPL) was significantly underexpressed in me ningioma compared with controls and especially in Grade II/III meningiomas compared with Grade I meningioma.
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The exact mechanism of its role in tumorigenesis, however, remains unclear.
Genome-Wide Analysis of Epigenetic Alterations
In addition to candidate gene studies, genomewide approaches have the advantage of examining all alterations in an unbiased manner. Earlier this year, we published a study comparing genomewide methylation patterns in benign, atypical, and malignant meningiomas. 26 To our knowledge, this is the first study to explore genome-scale DNA methylation in malignant, atypical, and benign me ningiomas. Additionally, unlike most previous cancer genetics studies that compare DNA methylation patterns between tumor and normal tissue, our goal was to investi gate whether benign and malignant tumors differ in DNA methylation patterns and whether these differences have biological and clinical significance. Compared with the benign tumors, the atypical and malignant meningiomas demonstrate increased global DNA hypomethylation. In terestingly, while hierarchical clustering analysis readily separates malignant from atypical and benign tumors, it cannot separate atypical and benign tumors, implicating that DNA methylation patterns may serve as diagnostic biomarkers for malignancy. Additionally, we investigated the correlation between methylation and gene expres sion. Most genes with hypermethylated CpG islands in promoter regions are suppressed in both malignant and benign meningiomas, suggesting the switching of gene silencing machinery from polycomb repressor complex (PRC) binding to DNA methylation in malignant me ningiomas. One exception is the MAL2 gene, which has high expression in levels in benign meningiomas but low expression in malignant tumors. MAL2 has hypermethyl ation at a CpG island in its promoter region in malignant meningiomas, therefore representing de novo gene silenc ing induced by DNA methylation.
In addition to methylation, alterations of histone modification and higher-order chromosomal structure represent additional epigenetic mechanisms that may reg ulate gene expression and function. Because of the avail ability of highthroughput sequencing, these studies have now become increasingly popular in molecular genetics studies. For example, the ChIP-sequencing (ChIP-seq) technique, which combines chromatin immuneprecipita tion with nextgeneration sequencing, can be used to ex amine histone modification patterns given antibodies for the specific modifications. Similarly, 3C, 4C, 5C, Hi-C and ChIAPET techniques, 18,20,82 were specifically devel oped for interrogating higherorder chromosomal struc tures between regulatory elements and target genes that may be located far away (even in different chromosomes). These techniques were becoming increasingly popular in molecular genetics studies of cancer. However, to our knowledge, these types of studies have not yet been re ported on meningiomas. It is expected that identification of additional epigenetic changes, such as histone modifi cation and higherorder chromosomal structure, may al low for a more thorough understanding of tumorigenesis and enable future individualized treatment strategies for meningiomas.
Discussion
The literature pertaining to epigenetic regulation of meningiomas demonstrates that progressively more methylated loci, in general, are associated with increas ing tumor grades. This is likely explained by widespread silencing of tumorsuppressor genes and pathways. This finding is also consistent with findings of previous studies showing that mutations within the genes themselves co incide with increasing tumor grade. 31, 52 In addition, there was a trend for Grade I and II meningiomas to have more hypermethylated loci than genetically mutated loci, high lighting the role that methylation plays in early menin gioma tumorigenesis, visàvis somatic mutations.
Aberrant DNA methylation is thought to silence genes and reduce expression by blocking transcription al machinery access to DNA. 35 This suggests that DNA methylation is potentially acquired before phenotypical changes and that aberrant methylation may be a harbinger of malignant transformation and recurrence.
Types of Epigenetic Alteration
Epigenetic alterations in the genome often occur in the early stages of tumorigenesis 35 through aberrant DNA methylation 45 -in particular, CpG island hypermethyl ation of promoter regions that results in tumorsuppres sor gene silencing and tumorigenesis.
6,35 Normally, many genes have promoter regions that are densely populated with CpG dinucleotides, termed CpG islands, which are maintained in an unmethylated state. Subsequent hyper methylation of these CpG islands at the promoter region has been shown to silence and inactivate gene expression downstream. If the gene is a growth inhibitor or DNA repair enzyme, for example, then growth goes unchecked, often leading to tumorigenesis. 33 In recent years, it has been shown that DNA methylation at non-CpG island sites may play as important a role in modulating gene expression as methylation occurring at promoter CpG is land sites.
Gene Methylation Detection Methods
In general, researchers use 2 approaches to detect aberrant epigenetic modifications: single-gene (targeted) approaches and genomewide assessments. The meth ylation status of single candidate genes can be screened for abnormal epigenetic modifications if they have been previously implicated or prioritized as playing a role in tumorigenesis or transformation, using techniques such as polymerase chain reaction or MethyLight. The single gene approach, however, is limited, as it only surveys a fraction of the possible modifications to that gene, while also being unable to study the role of additional genes that may contribute to oncogenesis or anaplasia. 77 Larger scale methods for detecting epigenetic involvement in meningiomas involve restriction landmark genome scan ning (RLGS), a two-dimensional gel-based method for assessing methylation status in thousands of CpG islands simultaneously. 32 Over the past decade, nextgeneration highthroughput techniques for assessing methylation status across the entire genome have become increasingly used to study meningiomas. 26 
Distinction Between Genetic and Epigenetic Mutation Targets
The most clearly established genetic mutation for me ningiomas is inactivation of the neurofibromin 2 (NF2) gene located on 22q, with the associated loss of its mer lin protein expression. 68, 73 NF2 mutations have been de tected in more than 50% of all sporadic meningiomas in all pathological grades, clearly showing that mutation of NF2 plays an important early role in meningioma devel opment. 89, 93 It should be surprising to note, then, that NF2 is not a frequent target of epigenetic modification.
25 An analysis of 40 CpG sites within 750 bp of the promoter regions of NF2 showed no methylation of these regions, 30 and the NF2 gene itself was methylated in only 1 of 21 tumors in a separate study. 91 Other mechanisms involved in loss of function of NF2, such as chromosomal deletions and primary mutations, are more likely to affect NF2 ex pression than are epigenetic alterations.
Other important genes that have been previously noted as significant in meningioma development but not found as targets of epigenetic target modification include ADAM23, 13 MGMT, CDKN2A, CDKN2B, CDKN2C, CDK N2D, and RB1 (RB). 73 Esteller al. previously re ported promoter hypermethylation of MGMT in various neoplasms throughout the body, 23 with rates ranging from 21% in lung cancers to 34% of all brain tumors. In me ningiomas, however, only 6% of MGMT promoters were hypermethylated in 1 group of 48 meningioma cases 49 and a separate group of 36 meningioma cases.
17 MGMT promoter hypermethylation was also not correlated with grade of the neoplasm.
37,94
Our results show that epigenetic and transcriptomic alterations in various tumor suppressors are likely to play an active role in meningioma development. We noted, however, that this mechanism of tumor progression did not seem to develop for RB1. CDKN2A (p16 [INK4A] ) and CDKN2B (p15 [INK4B] ) are genes on the 9p21 locus that regulate the transition from G 1 /S-phase checkpoint and interact with and RB1.
5 Loss of CDKN2A, CDKN2B, or RB1 activity through mutation or methylation would, in theory, disrupt the growthregulatory pathway and al low unrestrained cell proliferation. 49 However, the low frequency of methylation of CDKN2B (p15[INK4B] ),
8,49,88 along with RB1 genes sug gests that methylation of these growth control genes does not play a major role in the development of a majority of brain tumors.
97 CDKN2C (p18[INK4C] ) CDK inhibitors do not seem to have any role in meningioma progression as well, even though they serve a similar cell cycle regula tory function. 8 A subset of 67 meningiomas showed only a single tumor with any alterations at the CDKN2C locus. This lack of epigenetic modification applied to CDKN2D at 19q13 78 as well.
Accordingly, Boström et al. proposed that regula tion of CDKN transcription in meningiomas might be influenced by as yet unknown mechanisms in addition to hypermethylation. This may explain why genetic mecha nisms but not epigenetic mechanisms are crucial in me ningioma progression for the RB pathway. 8 
Future Directions
The divergence between genetic and epigenetic man ifestations in meningioma progression clearly illustrates the challenge that expression profiles attempt to portray in a phenotypically heterogenous neoplasm. It will be im portant to investigate expression profiles of more genes in a larger series of tumors with clinical followup data to ensure that genes are correlated to grade and clinical outcome as well.
Conclusions
We present here a comprehensive review of the epi genetic alterations of genes and corresponding changes in gene expression that may lead to meningioma devel opment, progression, and recurrence. Additional analysis and discovery of other genetic and epigenetic mecha nisms involved in meningioma pathogenesis is needed to fully understand this tumor's biology. Future research into potential primary or adjuvant treatments with de methylating and deacetylating agents will be important in elucidating their potential role in the management of meningiomas. 
